Biotron Ltd (ASX:BIT) until recently, was capturing investors’ attention through its BIT225 drug, which is in mid‑stage clinical development for treatment of HIV-1 and Hepatitis C virus (HCV) infection.
However, a company presentation dated 7 June 2019 has got investors intrigued, given the recent outbreak of the deadly coronavirus.
Furthermore, non-executive director Roberts Thomas purchased one million shares yesterday in an off-market purchase for $50,000.
This took his total holding in the company to 3.66 million shares.
This followed a $40,000 purchase on 10 January 2020 from fellow board member Stephen Locarnini.
Biotron could turn focus to coronavirus
With one of China’s most populated cities, Wuhan, being placed on lockdown today and the death toll from the coronavirus rising to 17, Biotron may increase its focus on the coronavirus.